RedHill Biopharma (RDHL) Scheduled to Post Earnings on Thursday

RedHill Biopharma (NASDAQ:RDHL) is scheduled to post its quarterly earnings results before the market opens on Thursday, February 22nd. Analysts expect RedHill Biopharma to post earnings of ($0.65) per share for the quarter.

RedHill Biopharma (NASDAQ:RDHL) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.18). The company had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.27 million. On average, analysts expect RedHill Biopharma to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

RedHill Biopharma (NASDAQ RDHL) opened at $5.90 on Thursday. The firm has a market cap of $123.81, a price-to-earnings ratio of -2.19 and a beta of 0.74. RedHill Biopharma has a fifty-two week low of $4.30 and a fifty-two week high of $11.25.

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of RedHill Biopharma in a report on Tuesday, November 21st. Zacks Investment Research upgraded shares of RedHill Biopharma from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a report on Friday, November 17th. Nomura initiated coverage on shares of RedHill Biopharma in a report on Friday, January 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Roth Capital decreased their price objective on shares of RedHill Biopharma from $27.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.58.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at

About RedHill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Earnings History for RedHill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with's FREE daily email newsletter.

Leave a Reply